Find a Doctor

VJ
Areas of Expertise

Vipul Jairath

Western University
Male

Bio

Vipul Jairath is in London, Canada. They have been an author on 239 peer reviewed articles and participated in 4 clinical trials in the past 15 years.

Areas of Expertise

Contact

London, ON, CA

Latest Advances

Latest Advance
Study
  • Condition: Ulcerative Colitis (UC)
  • Journal: Alimentary pharmacology & therapeutics
  • Treatment Used: Continuing vs Stopping 5-Aminosalicylates (5-ASA)
  • Number of Patients: 4068
  • Published —
This study evaluated continuing versus stopping 5-aminosalicylates (used to reduce inflammation in the body; 5-ASA) in patients with ulcerative colitis (an inflammatory bowel disease that causes long-lasting inflammation and sores in the digestive tract; UC) escalated to anti-metabolite therapy (a type of chemo drug that interferes with the normal metabolism of cells, which makes them stop growing).
Latest Advance
Study
  • Condition: Crohn's Disease (CD)
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Adalimumab
  • Number of Patients: 1158
  • Published —
This study assessed the effectiveness and safety of adalimumab for maintenance of remission in patients with Crohn's disease (chronic inflammatory disease of the digestive tract; CD).
Latest Advance
Study
  • Condition: Ulcerative Colitis in Remission
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Tofacitinib
  • Number of Patients: 395
  • Published —
This study assessed the effectiveness and safety of tofacitinib for the maintenance of remission in patients with ulcerative colitis.
Latest Advance
Study
  • Condition: Crohn's disease
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Anti-IL-12/23p40 antibodies (Ustekinumab and briakinumab)
  • Number of Patients: 646
  • Published —
The objectives of this review were to assess the effectiveness and safety of anti-IL-12/23p40 antibodies (target small proteins associated with Chrohn's disease) for maintenance of remission in Crohn's disease.
Latest Advance
Study
  • Condition: Crohn's disease
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Adalimumab
  • Number of Patients: 714
  • Published —
The aim of the study was to assess the effectiveness and safety of adalimumab (drug that suppresses the immune system) for the induction of remission in Crohn's disease.
Latest Advance
Study
  • Condition: Crohn's Disease
  • Journal: Alimentary pharmacology & therapeutics
  • Treatment Used: Janus Kinase Inhibitors
  • Number of Patients: 3450
  • Published —
In this study, researchers evaluated the safety and effectiveness of Janus kinase inhibitor medications for Crohn's disease.
Latest Advance
Study
  • Condition: Ulcerative Colitis (UC)
  • Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Treatment Used: Infliximab vs. Golimumab
  • Number of Patients: 0
  • Published —
This study compared the effectiveness and speed of onset of action of infliximab versus golimumab induction therapy in the treatment of ulcerative colitis (UC).
Latest Advance
Study
  • Condition: Crohn's Disease
  • Journal: Alimentary pharmacology & therapeutics
  • Treatment Used: Early Combined Immunosuppression
  • Number of Patients: 1981
  • Published —
This study tested the safety and efficacy of using an early combined immunosuppression to treat patients with Crohn's disease.
Latest Advance
Study
  • Condition: Inflammatory Bowel Disease
  • Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Treatment Used: Biologic or Immunosuppressive Therapy
  • Number of Patients: 0
  • Published —
This study investigated the risk of serious infections when using a biologic or immunosuppressive therapy to treat patients with inflammatory bowel disease.
Latest Advance
Study
  • Condition: Ulcerative Colitis (UC)
  • Journal: The American journal of gastroenterology
  • Treatment Used: Medical Therapies
  • Number of Patients: 0
  • Published —
This review of the literature examined the relationship between histologic and endoscopic outcomes of medical therapies for ulcerative colitis (UC).
Latest Advance
Study
  • Condition: Gastroduodenal Crohn's Disease Strictures
  • Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Treatment Used: Endoscopic Balloon Dilation
  • Number of Patients: 94
  • Published —
In this study, researchers evaluated the safety and effectiveness of undergoing endoscopic balloon dilation for the treatment of strictures of the upper gastrointestinal tract in patients with Crohn's disease.
Latest Advance
Study
  • Condition: Ulcerative colitis (UC) and colonic Crohn's disease (CD)
  • Journal: The American journal of gastroenterology
  • Treatment Used: Endoscopic surveillance
  • Number of Patients: 7199
  • Published —
This extensive review of the literature evaluated the effectiveness of endoscopic surveillance for patients with ulcerative colitis (UC), Crohn's disease (CD) and how this intervention improves early colorectal cancer (CRC) and reduce mortality rates in this population of patients.
Latest Advance
Study
  • Condition: Fistulizing Crohn's Disease
  • Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • Treatment Used: Various
  • Number of Patients: 0
  • Published —
In this review of the literature, researchers sought to determine the best treatment for fistulizing Crohn's disease.

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Genetic, Other
  • Participants: 162
  • Start Date: September 1, 2020
Pharmacogenomic Strategies in Inflammatory Bowel Disease: Evaluating the Role of Pre-emptive HLADQA1 Genotyping for the Application of Targeted Infliximab-based Combination Therapy (INHERIT)
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Drug
  • Participants: 30
  • Start Date: December 21, 2018
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 1044
  • Start Date: October 19, 2018
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 840
  • Start Date: July 18, 2018
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

All Publications
View All

Publication
Study
  • Journal: Inflammatory bowel diseases
  • Published —
Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn's Disease.
Publication
Study
  • Journal: Inflammatory bowel diseases
  • Published —
Tofacitinib Induced Long-term Clinical, Endoscopic, and Histological Remission as a 6th Line Agent in Medically Refractory Ulcerative Colitis.

Contact

London, ON, CA

Insurance

Contact them to find out if they accept your insurance plan.